In short
Valbenazine Ditosylate, a promising drug candidate, is currently being studied in clinical trials for its potential in treating various neurological and psychiatric conditions. These trials aim to evaluate the efficacy, safety, and tolerability of Valbenazine as an adjunctive treatment for schizophrenia and as a potential therapy for dyskinesia due to cerebral palsy. The ongoing research seeks to address unmet medical needs and improve the quality of life for patients with these challenging disorders.
At a glance
- Drug Name
- Valbenazine Ditosylate
- Conditions Studied
- Schizophrenia, Dyskinesia due to cerebral palsy
- Trial Phases
- Phase 3
- Administration
- Oral capsules
- Primary Objectives
- Evaluate efficacy, safety, and tolerability
- Key Measures
- PANSS scores, CGI-S scores, TMC scores, PSP scores
- Patient Groups
- Adults with schizophrenia or dyskinesia due to cerebral palsy
- Study Design
- Randomized, double-blind, placebo-controlled
What is Valbenazine?
Valbenazine Ditosylate, also known as Valbenazine Tosylate or simply Valbenazine, is a medication being studied for its potential to treat certain movement disorders. It is developed by Neurocrine Biosciences Inc. and is currently undergoing clinical trials to evaluate its effectiveness and safety.
How Does It Work?
Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor. VMAT2 is a protein in the brain that helps package and transport certain chemicals (neurotransmitters) between brain cells. By inhibiting VMAT2, Valbenazine can help regulate the levels of these neurotransmitters, which may help control involuntary movements associated with certain disorders.
What Conditions Does Valbenazine Treat?
Based on the ongoing clinical trials, Valbenazine is being studied for its potential to treat:
- Schizophrenia: Specifically, it's being tested as an adjunctive (add-on) treatment for people with schizophrenia who have inadequate response to antipsychotic treatment.
- Dyskinesia due to Cerebral Palsy (DCP): This includes choreiform movements, which are irregular, unpredictable, dance-like movements.
It's important to note that while these conditions are the focus of current studies, Valbenazine is not yet approved for treating these disorders. The clinical trials aim to determine its effectiveness and safety for these uses.
How is Valbenazine Administered?
Valbenazine is being tested in the form of oral capsules. In the clinical trials, it's being administered once daily. The dosage varies depending on the study and condition being treated, ranging from 30 mg to 80 mg per day.
Current Clinical Trials
There are currently two Phase 3 clinical trials studying Valbenazine:
- Study for Schizophrenia: This trial is evaluating Valbenazine as an adjunctive treatment for people with schizophrenia who don't respond adequately to antipsychotic treatment. The main goal is to see if Valbenazine can improve schizophrenia symptoms compared to a placebo.
- Study for Dyskinesia due to Cerebral Palsy: This trial is testing Valbenazine in both children and adults with dyskinesia (abnormal movements) caused by cerebral palsy. The primary aim is to see if Valbenazine can improve chorea (a type of involuntary movement) in these patients.
Both studies are randomized, double-blind, and placebo-controlled, which means participants are randomly assigned to receive either Valbenazine or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study.
Potential Side Effects and Precautions
As Valbenazine is still in clinical trials, its full side effect profile is not yet known. However, based on the exclusion criteria in the studies, some precautions are being taken for people with:
- History of long QT syndrome or cardiac arrhythmia
- Moderate or severe liver problems
- History of neuroleptic malignant syndrome
- Substance use disorders
- Suicidal thoughts or behaviors
It's important to remember that these are precautionary measures for the clinical trials and don't necessarily reflect confirmed side effects or contraindications.
As with any medication, if Valbenazine becomes approved for use, it will be crucial to discuss potential risks and benefits with a healthcare provider before starting treatment.